|Bid||12.00 x 900|
|Ask||12.16 x 900|
|Day's range||11.09 - 12.25|
|52-week range||7.08 - 40.91|
|Beta (5Y monthly)||2.24|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Aug 1996|
|1y target est||N/A|
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study.
On June 28, shares of Cel-Sci (NYSEMKT: CVM) plunged nearly 70% peak-to-trough before recovering. The reason behind the wild price action couldn't be more obvious -- the company's pivotal phase 3 study involving its Multikine immunotherapy did not meet its primary endpoint of improving the overall survival (OS) of head and neck cancer patients. Cel-Sci had been extremely popular among traders of the r/WallStreetBets community due to its short interest -- standing as high as 24% before the data release.